Inclusion Criteria:  Provision of signed and dated informed consent form. Stated willingness to comply with all study procedures and availability for the duration of the study. Male or female, aged 40-85 yrs old Subject has IPF satisfying the 2018 ATS/ERS/JRS/ALAT diagnostic criteria. Subject must have been on a stable dose of nintedanib or pirfenidone for at least 12 weeks. Subject has a FVC>50%. Subject has a DLCO>35%. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if <55 years or 12 months if >55 years, must have a negative serum pregnancy test within 1 week prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence. Subject has a life expectancy of at least 9 months. Ability to take oral medication and be willing to adhere to EGCG regimen. Agreement to refrain from drinking green tea in excess of a cup a day or eating green tea extract for 4 weeks before baseline and during the trial.  Exclusion Criteria:  AST, ALT, or direct bilirubin above upper limit normal from any cause Any history of HCV or HBV infection, NASH/NAFLD, or cirrhosis Alcohol consumption greater than 7 drinks per week Subject has emphysema >50% on HRCT or the extent of emphysema is greater than the extent of fibrosis according to reported results from the most recent HRCT Subject has a history of cigarette smoking within the previous 3 months Subject has received investigational therapy for IPF within 4 weeks before baseline Subject is receiving systemic corticosteroids equivalent to prednisone > 10 mg/day or equivalent within 2 weeks of baseline Subject has any concurrent condition other than IPF that, in the Investigator's opinion, is unstable and/or would impact the likelihood of survival for the study duration or the subject's ability to complete the study as designed, or may influence any of the safety or efficacy assessments included in the study. Subject has baseline resting oxygen saturation of < 89% on room air or need for continuous oxygen use. Consumption of green tea extract products in excess of a cup of green tea a day within one month of enrollment. Subject is receiving digoxin.